LUND, Sweden, Oct. 30, 2024 /PRNewswire/ — Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA) today announced it will attend Truist Securities BioPharma Symposium on November 7 in New York, NY. Hitto Kaufmann, Chief R&D Officer at […]
Tag: Hansa Biopharma AB
Hansa Biopharma to Attend Truist Securities BioPharma Symposium
LUND, Sweden, Oct. 30, 2024 /PRNewswire/ — Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA) today announced it will attend Truist Securities BioPharma Symposium on November 7 in New York, NY. Hitto Kaufmann, Chief R&D Officer at […]
Hansa Biopharma Reports Third Quarter and Interim January
Q3 2024 marks highest ever in-market quarterly sales performance and fourth consecutive quarter of strong sales performance LUND, Sweden, Oct. 17, 2024 /PRNewswire/ — Hansa Biopharma today announced its interim report for January-September and third […]
Hansa Biopharma Reports Third Quarter and Interim January
Q3 2024 marks highest ever in-market quarterly sales performance and fourth consecutive quarter of strong sales performance LUND, Sweden, Oct. 17, 2024 /PRNewswire/ — Hansa Biopharma today announced its interim report for January-September and third […]
Hansa Biopharma’s HNSA-5487 Achieved Rapid and Highly Robust IgG Reduction by More Than 95% and Clear Redosing Potential in First-in-Human Trial
LUND, Sweden, Oct. 7, 2024 /PRNewswire/ — Hansa Biopharma AB, (“Hansa” or the “Company”) (NASDAQ STOCKHOLM: HNSA), today announced positive results from a 12-month follow up analysis from the NICE-01 trial of HNSA-5487, the Company’s next […]